Nourianz is supplied in 20 and 40mg tablet strengths. Dosage adjustments are recommended in patients with hepatic impairment, those taking strong CYP43A4 inhibitors, as well as tobacco smokers.

SILVER SPRING, Md., Aug. 27, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa in adult ...

The Food and Drug Administration (FDA) has approved Nourianz (istradefylline; Kyowa Kirin) tablets as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD ...

BEDMINSTER, N.J.--(BUSINESS WIRE)--Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ™ (istradefylline) is now available in the U.S ...

KW-6356 is a follow-up to Kyowa Kirin's first-generation adenosine A2 antagonist Nourianz/Nouriast (istradefylline), which finally claimed FDA approval in 2019 as an add-on to levodopa in ...

Nourianz (istradefylline) is sometimes prescribed alongside carbidopa and levodopa. Although its exact mechanism of action is unknown, it is believed to block adenosine receptors. It is ...

The effort includes an updated patient website (www.Nourianz.com) with dynamic content, a patient video, and resources that explain the role of dopamine and adenosine in Parkinson's disease ...